Filspari™ (sparsentan) – New orphan drug approval
February 17, 2023 - Travere Therapeutics announced the FDA approval of Filspari (sparsentan), to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) ≥ 1.5 g/g.
Top